Compare LIDR & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIDR | SLGL |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 117.8M |
| IPO Year | N/A | 2018 |
| Metric | LIDR | SLGL |
|---|---|---|
| Price | $2.19 | $53.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.4M | 18.9K |
| Earning Date | 02-19-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $182,000.00 | ★ $18,970,000.00 |
| Revenue This Year | $2.76 | $121.82 |
| Revenue Next Year | $2,830.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $0.49 | $4.02 |
| 52 Week High | $6.44 | $52.26 |
| Indicator | LIDR | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 71.05 |
| Support Level | $2.09 | $40.10 |
| Resistance Level | $2.32 | $44.99 |
| Average True Range (ATR) | 0.13 | 3.02 |
| MACD | 0.00 | 0.51 |
| Stochastic Oscillator | 61.61 | 81.93 |
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.